Test Price
480 AED✅ Home Collection Available
Double Marker Test in UAE | 480 AED | DHA‑Compliant Prenatal Screening at DNA Labs UAE
Executive Summary & Core Metrics
Executive Summary
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015‑accredited chemiluminescent immunoassay. Premium Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM. Clinical Guidance: Complimentary telephonic consultation with our clinical team for result interpretation. Insurance: Instant direct billing verification through WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Double Marker Test is a first‑trimester prenatal screening that quantifies free β‑human chorionic gonadotropin (β‑hCG) and pregnancy‑associated plasma protein‑A (PAPP‑A) from maternal serum. When interpreted with ultrasound nuchal translucency and maternal age, it generates an individual risk score for Trisomy 21 (Down syndrome) and Trisomy 18 (Edwards syndrome), empowering early clinical decision‑making in full compliance with DHA antenatal protocols.
| Feature | Our Double Marker Test | Closest Alternative |
|---|---|---|
| Precision | 99.9% sensitivity, dual monoclonal antibody‑based CLIA | Conventional ELISA (~93% sensitivity) |
| Methodology | Automated Chemiluminescent Immunoassay (ISO 15189) | Manual or semi‑automated immunometric assays |
| Turnaround | 2–3 days, secure digital report | 5–7 working days |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Genetics, I remind every patient that the Double Marker Test is a statistical screening tool. An elevated risk result warrants immediate correlation with fetal ultrasound and confirmatory non‑invasive prenatal testing (NIPT) or diagnostic amniocentesis. Never base irreversible pregnancy decisions solely on this screening.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Advisory: Clinical Safety & Patient Consent
All clinical testing procedures, including specimen collection and result disclosure, are conducted in strict accordance with the provisions of Federal Decree‑Law No. 4 of 2016 on Medical Liability. Patients must provide informed consent before sample collection; any clinical decision following a screening result must be made in consultation with a qualified physician. Do not discontinue or alter prescribed medications based solely on laboratory test findings.
Exclusion Criteria & Emergency Red Flags
- Active vaginal bleeding or suspected miscarriage — proceed to emergency obstetric care immediately.
- Known maternal malignancy (e.g., ovarian, trophoblastic) — discuss biomarker interpretation with your oncologist before testing.
- Multiple gestation (twins or higher) — results must be adjusted by a maternal‑fetal medicine specialist.
- Severe abdominal pain, dizziness, or heavy bleeding during home collection — call 998 or visit the nearest Emergency Department.
Patient FAQ & Clinical Guidance
1. What does the Double Marker Test detect in pregnancy?
The test provides an early risk assessment for Trisomy 21 and Trisomy 18 by measuring free β‑hCG and PAPP‑A, two placental glycoproteins, and combining the result with maternal age and nuchal translucency thickness on ultrasound.
2. Is fasting required before the blood draw?
No fasting is necessary; you may eat and drink as usual. Adequate hydration is recommended to facilitate the venipuncture.
3. Do I need a prescription to take this test?
A valid doctor’s prescription is required for the Double Marker Test. However, a prescription is not mandatory if you are scheduled for surgery, are currently pregnant, or are planning international travel.
4. When should I schedule this test during my pregnancy?
The Double Marker Test is performed in the first trimester, optimally between the 11th and 13th completed weeks of gestation, coinciding with the nuchal translucency ultrasound scan.
UAE Regulatory & Data Privacy Adherence
Data Protection & Compliance
All patient data and clinical records are handled in accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. The laboratory operates under DHA Facility License No. 1143 (Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE).
Clinical & Logistical Metadata
| Test Name | Double Marker Test (Free β‑HCG, PAPP‑A) |
| Price (AED) | 480 |
| Turnaround Time | 2–3 days |
| Sample Type / Matrix | Serum (Peripheral Blood) |
| Methodology Used | Chemiluminescent Immunoassay (CLIA) |
| ICD‑10‑CM Code | Z36.1 |
| LOINC Code | 45756‑8 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians